title: Expression profiles of vault components MVP, TEP1 and vPARP and their correlation to other multidrug resistance proteins in ovarian cancer.
abstract: Vaults are cytoplasmic ribonucleoprotein particles composed of three proteins (MVP, TEP1, vPARP) and vault‑associated RNAs (vRNAs). Although the cellular functions of vaults remain unclear, vaults are strongly linked to the development of multidrug resistance (MDR), the major obstacle to the efficient treatment of cancers. Available published data suggest that vaults and their components are frequently upregulated in broad variety of multidrug-resistant cancer cell lines and tumors of different histological origin. Here, we provide detailed analysis of vault protein expression in post-surgery ovarian cancer samples from patients that were not exposed to chemotherapy. Our analysis suggests that vault proteins are expressed in the ovaries of healthy individuals but their expression in cancer patients is changed. Specifically, MVP, TEP1 and vPARP mRNA levels are significantly decreased in cancer samples with tendency of lower expression in higher-grade tumors. The pattern of vault protein mRNA expression is strongly correlated with the expression of other MDR-associated proteins such as MDR1, MRP1 and BCRP. Surprisingly, the protein levels of MVP, TEP1 and vPARP are actually increased in the higher‑grade tumors suggesting existence of post-transcriptional regulation of vault component production.
authors.affiliation: Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznań, Poland. witold@ump.edu.pl
authors.forename: Witold
authors.initials: W
authors.lastname: Szaflarski
authors.forename: Patrycja
authors.initials: P
authors.lastname: Sujka-Kordowska
authors.forename: Bartosz
authors.initials: B
authors.lastname: Pula
authors.forename: Karolina
authors.initials: K
authors.lastname: Jaszczyńska-Nowinka
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Andrzejewska
authors.forename: Piotr
authors.initials: P
authors.lastname: Zawierucha
authors.forename: Piotr
authors.initials: P
authors.lastname: Dziegiel
authors.forename: Michał
authors.initials: M
authors.lastname: Nowicki
authors.forename: Pavel
authors.initials: P
authors.lastname: Ivanov
authors.forename: Maciej
authors.initials: M
authors.lastname: Zabel
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000096:biosynthesis; D002352:Carrier Proteins / Q000235:genetics*; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000096:biosynthesis; D009363:Neoplasm Proteins / Q000096:biosynthesis; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000601:surgery; D011065:Poly(ADP-ribose) Polymerases / Q000235:genetics*; D012333:RNA, Messenger / Q000096:biosynthesis; D016601:RNA-Binding Proteins; D014407:Tumor Cells, Cultured; D015854:Up-Regulation; D020394:Vault Ribonucleoprotein Particles / Q000235:genetics*; D000099187:Major Vault Protein
chemical_list: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; D002352:Carrier Proteins; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D009363:Neoplasm Proteins; D011065:Poly(ADP-ribose) Polymerases; D012333:RNA, Messenger; D016601:RNA-Binding Proteins; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein; C513055:ABCB1 protein, human; C116614:ABCG2 protein, human; C104342:TEP1 protein, human; C449359:vault poly(ADP-ribose) polymerase; C421109:multidrug resistance-associated protein 1